Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Buy Senores Pharma; target of Rs 1640: Choice Institutional Equities
Choice Institutional Equities is bullish on Senores Pharma has recommended buy rating on the stock with a target price of Rs 1640 in its research report dated July 08, 2026.
Closing Bell: Sensex, Nifty end flat amid volatility; pharma, oil & gas gain, media falls
Bharat Electronics, Adani Ports, Sun Pharma, Bharti Airtel, Maruti Suzuki were among major gainers on the Sensex, while losers were Power Grid Corporation, Trent, Bajaj Finserv, HDFC Bank and Eternal. Among sectors, auto, pharma, oil & gas, PSU Bank telecom, metal added 0.4-1%, while media index shed 0.7%. Nifty Midcap index rose 0.6%, while smallcap index ended flat.
Markets Erase Gains! Sensex, Nifty See Sharp Pullback | Closing Bell
Indian equity markets turned volatile with the Sensex tumbling over 400 points from the day’s high and the Nifty slipping nearly 100 points. Broader markets remained mixed as smallcaps saw selling pressure. While Realty and FMCG stocks stayed under stress, the Nifty Pharma index extended gains for the fifth straight session. IT stocks also attracted buying interest for the second consecutive day. Catch Lovisha Darad in conversation with market expert Anshul Saigal and Nilesh Jain, Head VP – Derivative and Technical Research at Centrum Broking Ltd, for detailed market insights and strategy.
Sun Pharma to use Organon deal to revive brands, expand licensing pipeline
MD Kirti Ganorkar said Organon’s commercial footprint gives Sun Pharma a ready‑made engine to in‑license near‑approval products and scale them quickly across markets
Neutral Torrent Pharma; target of Rs 4300: Motilal Oswal
Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 4300 in its research report dated February 14, 2026.
Buy Sun Pharmaceutical Industries; target of Rs 2000: ICICI Securities
ICICI Securities is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated April 28, 2026.
PSL offloads 0.6% stake in Sun Pharma Advanced Research, Motilal Oswal buys additional 0.7% stake in Adisoft
Sun Pharma Advanced Research Company shares fell 3.72 percent to Rs 143.04 amid high volumes
SPARC sells of priority review voucher in US for $195 million
PRV was granted by the US Food and Drug Administration (USFDA) for the approval of Sezaby indicated for the treatment of neonatal seizures
Buy Piramal Pharma; target of Rs 190: Motilal Oswal
Motilal Oswal is bullish on Piramal Pharma has recommended buy rating on the stock with a target price of Rs 190 in its research report dated April 29, 2026.
Buy Mankind Pharma; target of Rs 2640: Motilal Oswal
Motilal Oswal is bullish on Mankind Pharma has recommended buy rating on the stock with a target price of Rs 2640 in its research report dated April 29, 2026.
Orchid Pharma nears US licensing deal for novel antibiotic, talks in advanced stage
Enmetazobactam, when combined with cefepime, is used to treat serious bacterial infections, including complicated urinary tract and kidney infections. The therapy secured US regulatory approval in February 2024
Cipla, Sun Pharma, Dr Reddy's, Glenmark trade lower after Centre tightens cough syrup sales rules
The broader Nifty Pharma index also traded lower, falling 0.47% to 24,220.10.